RXRX Recursion Pharmaceuticals
AI drug discovery with NVIDIA-backed compute
Fundamentals from public market data, refreshed daily (2026-10-30 21:21 UTC). Figures in reporting currency.
RXRX · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-08-05EarningsMiss / cut
Reported EPS -0.25 vs -0.23 expected (-6.8% surprise).
-
7
2026-05-06EarningsBeat / raise
Reported EPS -0.22 vs -0.26 expected (+14.4% surprise).
-
6
2026-02-25EarningsBeat / raise
Reported EPS -0.21 vs -0.32 expected (+33.3% surprise).
-
5
2025-11-05EarningsBeat / raise
Reported EPS -0.36 vs -0.38 expected (+5.7% surprise).
-
4
2025-08-05EarningsMiss / cut
Reported EPS -0.41 vs -0.35 expected (-16.0% surprise).
-
3
2025-05-05EarningsBeat / raise
Reported EPS -0.5 vs -0.52 expected (+3.1% surprise).
-
2
2025-02-28EarningsMiss / cut
Reported EPS -0.53 vs -0.42 expected (-27.2% surprise).
-
1
2024-11-06EarningsMiss / cut
Reported EPS -0.34 vs -0.33 expected (-2.1% surprise).
Latest headlines
Auto-updated daily- Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back Rally2026-10-30
- Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?2026-10-29
- Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release2026-10-28
- Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider2026-10-26
- Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 32026-10-26
- Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing2026-10-20
- Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?2026-10-19
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.23 | -0.25 | −6.8% |
| 2026-05-06 | -0.26 | -0.22 | +14.4% |
| 2026-02-25 | -0.32 | -0.21 | +33.3% |
| 2025-11-05 | -0.38 | -0.36 | +5.7% |
| 2025-08-05 | -0.35 | -0.41 | −16.0% |
| 2025-05-05 | -0.52 | -0.5 | +3.1% |
| 2025-02-28 | -0.42 | -0.53 | −27.2% |
| 2024-11-06 | -0.33 | -0.34 | −2.1% |
| 2024-08-08 | -0.38 | -0.4 | −4.2% |
| 2024-05-09 | -0.43 | -0.39 | +8.6% |
| 2024-02-27 | -0.45 | -0.42 | +6.4% |
| 2023-11-09 | -0.39 | -0.43 | −11.6% |
| 2023-08-08 | -0.37 | -0.38 | −1.3% |
| 2023-05-08 | -0.35 | -0.34 | +3.0% |
| 2023-02-27 | -0.24 | -0.3 | −26.8% |
| 2022-11-08 | -0.38 | -0.35 | +7.6% |
| 2022-08-09 | -0.37 | -0.38 | −1.8% |
| 2022-05-10 | 0.51 | -0.33 | −164.7% |
| 2022-03-23 | -0.31 | -0.38 | −23.6% |
| 2021-11-10 | -0.28 | -0.28 | +0.1% |
| 2021-08-13 | -0.24 | -0.31 | −28.6% |
| 2021-05-12 | -0.23 | -0.23 | +1.0% |
About Recursion Pharmaceuticals
Website ↗Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes R…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| SDGR Schrödinger | Physics-plus-AI molecular design software | $27.14 | −9.50% | −10.9% | +51.8% | |
| ABSI Absci | Generative-AI antibody design | $11.13 | −8.02% | +3.5% | +218.9% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.27 | −6.19% | −11.8% | +258.8% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $72.22 | −7.22% | −5.6% | +22.3% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.